• Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World
Newsy Today
news of today
Home - Drug Delivery
Tag:

Drug Delivery

Health

Low-frequency ultrasound waves directly manipulate blood flow properties

by Chief Editor May 18, 2026
written by Chief Editor

The Evolution of Ultrasound: From Seeing the Body to Healing It

For decades, the medical world has viewed ultrasound primarily as a window into the human body. Whether it is the first glimpse of a developing fetus or a routine check of internal organs, ultrasound has been the gold standard for non-invasive diagnostics. However, a paradigm shift is occurring. We are moving from a period of “diagnostic imaging” into an era of “mechanical therapy.”

Recent breakthroughs from researchers at the Kaunas University of Technology (KTU) suggest that sound waves can do more than just create an image—they can actively manipulate the physical properties of our blood. By utilizing specific frequencies, scientists are discovering how to influence blood flow and oxygen delivery, potentially transforming the treatment of chronic and acute diseases.

Did you know? The research team at KTU developed a low-frequency ultrasound transducer that can send acoustic signals approximately four times deeper into biological tissues than conventional devices. This technology is now protected by an international patent.

The Frequency Divide: Aggregation vs. Dissociation

The core of this discovery lies in how different sound frequencies interact with red blood cells, also known as erythrocytes. These cells naturally form reversible clusters called aggregates, which directly impact blood viscosity. Viscosity is a critical factor in how efficiently oxygen is transported throughout the body.

The Impact of High-Frequency Ultrasound

High-frequency ultrasound creates standing acoustic waves. These waves drive erythrocytes toward low-pressure regions, which encourages them to cluster together. According to Vytautas Ostaševičius, a KTU professor and lead author of the study, “When erythrocytes cluster together under the influence of high-frequency ultrasound, blood viscosity increases, blood pressure and pulse may rise, and oxygen exchange becomes less efficient.”

The Breakthrough of Low-Frequency Ultrasound

In contrast, low-frequency ultrasound generates travelling acoustic waves. These waves create shear forces that can break apart those clusters, separating aggregated erythrocytes into single cells. This process creates gaps between the cells, decreasing blood viscosity and allowing the entire surface of the cell to participate in oxygen exchange.

As Ostaševičius, director of the KTU Institute of Mechatronics, notes, “To our knowledge, this effect has not previously been demonstrated.”

Future Medical Frontiers: Where Sound Meets Therapy

While this technology is currently in the experimental stage, its implications for the future of medicine are vast. By mechanically influencing blood properties, clinicians may one day reduce the reliance on invasive surgeries and heavy medication.

Targeting Cancer and Tumors

One of the most promising applications is in oncology. Tumors are often characterized by low oxygen levels, which can hinder the effectiveness of certain treatments. Because tumor tissue is typically mechanically weaker than healthy surrounding tissue, travelling acoustic waves may be used to selectively improve local oxygen delivery, potentially increasing the efficacy of cancer therapies.

Targeting Cancer and Tumors
red blood cells ultrasound

Combatting Alzheimer’s and Neurological Barriers

The blood-brain barrier is a protective shield that prevents many medications from reaching brain tissue. Researchers are exploring the use of low-frequency ultrasound as a way to temporarily open this barrier. This could revolutionize the treatment of Alzheimer’s disease by allowing for more precise, targeted drug delivery directly into the brain.

Healing Diabetic Foot Ulcers

Diabetes often leads to impaired circulation, particularly in the extremities, making wound healing difficult and increasing the risk of amputation. By using ultrasound to improve blood flow in affected tissues, medical professionals may be able to accelerate the healing of diabetic foot ulcers.

Blood Circulation Frequency: Rife Frequency for Better Blood Flow
Pro Tip for Healthcare Innovators: Keep a close eye on “digital twin” technology. The KTU team used digital twins to develop their high-penetration transducer, demonstrating how virtual modeling is drastically shortening the R&D cycle for medical hardware.

A New Era of Non-Invasive Care

The origin of this research is a testament to the agility of modern science; the idea emerged during the COVID-19 pandemic as scientists sought non-invasive ways to help patients with severe respiratory complications. The goal was to intensify the interaction between haemoglobin and oxygen in the lungs without the use of medication.

This shift toward mechanical influence represents a broader trend in medicine: the move toward supportive therapies for cardiovascular and pulmonary diseases that complement existing surgical and pharmacological treatments. As Ostaševičius explains, “Our work shows that ultrasound can mechanically influence blood properties. This opens possibilities for future non-invasive therapies.”

For more detailed technical data on these findings, you can explore the full study, “Advances in Ultrasonic Rehabilitation,” published in the journal Sensors.

Frequently Asked Questions

Is this ultrasound therapy available in hospitals now?

No, this technology is currently in the early research and experimental stage. It is not yet a standard clinical treatment, but it provides a foundation for future non-invasive therapies.

Is this ultrasound therapy available in hospitals now?
microscopic blood circulation

How does low-frequency ultrasound differ from a standard ultrasound scan?

A standard scan uses ultrasound for diagnostics (imaging). This research focuses on using low-frequency waves as a therapeutic tool to physically separate red blood cell aggregates and improve blood flow.

Can ultrasound really help with Alzheimer’s?

The research suggests a potential future application where ultrasound could temporarily open the blood-brain barrier to improve the delivery of targeted drugs to brain tissue.

Does this technology replace medication?

The goal is not necessarily to replace medication, but to provide a non-invasive complement to existing surgical and drug-based treatments.


What are your thoughts on the future of non-invasive medicine? Do you believe sound-wave therapy will eventually replace some of our current surgical procedures? Let us know in the comments below or subscribe to our newsletter for the latest updates in medical innovation.

May 18, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

ExiVex reports in-human pharmacokinetic data showing EMRX-101 intranasal naloxone approaches IV-like peak plasma concentrations with substantially faster Tmax than currently approved comparator

by Chief Editor May 15, 2026
written by Chief Editor

The Race Against Time: The Evolution of Rapid-Onset Emergency Therapeutics

In the high-stakes environment of emergency medicine, the difference between a successful intervention and a tragic outcome is often measured in seconds. As the landscape of opioid crises evolves—particularly with the prevalence of high-potency synthetic opioids like fentanyl—the demand for faster, more potent delivery systems has never been more urgent.

Traditional intranasal delivery has long been a staple for overdose reversal due to its ease of use. However, first-generation devices often struggle with absorption limits and inconsistent dosing. The industry is now shifting toward “IV-like” speed through the nose, aiming to bridge the gap between the convenience of a spray and the immediate impact of an intravenous injection.

Did you know? In a recent exploratory study of healthy volunteers, the candidate EMRX-101 demonstrated a peak plasma concentration (Tmax) of approximately 6-10 minutes, significantly faster than the approximately 25 minutes associated with currently approved 4 mg intranasal naloxone.

Breaking the Absorption Barrier: The Dual-Chamber Innovation

The primary challenge with nasal delivery has always been the “absorption ceiling.” To overcome this, pharmaceutical innovators are moving toward proprietary dual-chamber platforms. These systems are engineered to optimize the formulation and delivery mechanism simultaneously, ensuring that the drug is not just delivered, but absorbed with maximum efficiency.

ExiVex Biopharma (formerly EmerRx Biopharma) is currently pioneering this approach with its lead candidate, EMRX-101. By utilizing a PK-optimized formulation, the platform aims to solve the dose-consistency and Tmax limitations that have hindered previous generations of intranasal drug-device combinations.

The Data Behind the Speed

Recent pharmacokinetic (PK) data highlights the potential magnitude of this shift. In a study of 13 healthy volunteers, EMRX-101 (4 mg) achieved:

  • Higher Early Exposure: Approximately 13.7-fold higher cumulative exposure in the first two minutes (AUC0–2) compared to the approved comparator.
  • Increased Peak Concentration: Approximately 3.1-fold higher Cmax.
  • IV-Like Levels: A peak plasma naloxone concentration of approximately 14 ng/mL.

“These data reinforce our conviction that the dual-chamber platform can meaningfully improve the speed and magnitude of naloxone delivery in emergency settings, where every minute matters,” says Mitch Raponi, Co-Founder and CEO of ExiVex.

Future Trends: Beyond Opioid Reversal

While naloxone is the immediate priority, the implications of a high-speed intranasal platform extend far beyond overdose reversal. The ability to achieve rapid systemic exposure through the nasal cavity opens the door for a variety of acute and emergency rescue indications, particularly those targeting the Central Nervous System (CNS).

The trend is moving toward a “platform architecture” model. Instead of developing a single drug, companies are building a common underlying device and formulation framework. This allows for a pipeline of differentiated products that can be deployed across various emergency uses, utilizing the same proven delivery logic.

Pro Tip for Industry Observers: Keep an eye on the 505(b)(2) regulatory pathway. This pathway allows companies to leverage existing safety and efficacy data, potentially accelerating the timeline from clinical trials to final approval—a strategy ExiVex is currently employing for EMRX-101.

Navigating the Regulatory Path to 2028

The journey from a successful PK study to a pharmacy shelf requires a strategic regulatory approach. The goal for next-generation therapeutics is to streamline the process through single registrational PK studies. By aligning with FDA agreements early, developers can target specific approval windows—such as the 2028 goal set for EMRX-101—while advancing IND-enabling activities.

Navigating the Regulatory Path to 2028
Biopharma

As these technologies mature, the focus will likely shift toward expanding the “emergency-use” toolkit, moving from single-use rescue medications to a broader suite of rapid-response CNS therapeutics that can be administered by first responders or bystanders without the need for invasive procedures.

Frequently Asked Questions

What is EMRX-101?
EMRX-101 is an intranasal naloxone product developed by ExiVex Biopharma, designed to treat opioid-induced respiratory depression using a proprietary dual-chamber delivery platform.

Why is “early systemic exposure” important?
In the “fentanyl era,” the first few minutes of an overdose are critical. Higher exposure in the first two minutes can lead to faster reversal of respiratory depression, potentially improving clinical outcomes.

How does a dual-chamber device differ from a standard nasal spray?
Unlike first-generation sprays, a dual-chamber platform optimizes both the formulation and the delivery mechanism to overcome absorption limits and ensure more consistent dosing.


What are your thoughts on the shift toward IV-like nasal delivery? Do you believe this will become the gold standard for emergency rescue? Let us know in the comments below or subscribe to our newsletter for the latest updates in pharmaceutical innovation.

May 15, 2026 0 comments
0 FacebookTwitterPinterestEmail

Recent Posts

  • Woman Criticized for Bringing Own Ingredients and Clearing Out Snacks at Haidilao

    July 11, 2026
  • Historical Massacres Strain Poland-Ukraine Relations

    July 11, 2026
  • Maya’s Silence in Nuno Homem de Sá’s Domestic Violence Trial – Vidas

    July 11, 2026
  • MotoGP German GP: Qualifying and Pole Position Live Coverage

    July 11, 2026
  • The Volatile Rollercoaster of Fuel Prices

    July 11, 2026

Popular Posts

  • 1

    Maya Jama flaunts her taut midriff in a white crop top and denim jeans during holiday as she shares New York pub crawl story

    April 5, 2025
  • 2

    Saar-Unternehmen hoffen auf tiefgreifende Reformen

    March 26, 2025
  • 3

    Marta Daddato: vita e racconti tra YouTube e podcast

    April 7, 2025
  • 4

    Unlocking Success: Why the FPÖ Could Outperform Projections and Transform Austria’s Political Landscape

    April 26, 2025
  • 5

    Mecimapro Apologizes for DAY6 Concert Chaos: Understanding the Controversy

    May 6, 2025

Follow Me

Follow Me
  • Cookie Policy
  • CORRECTIONS POLICY
  • PRIVACY POLICY
  • TERMS OF SERVICE

© 2026 Newsy Today. All rights reserved.
For contact, advertising, copyright, issues email: [email protected]


Back To Top

For contact, advertising, copyright, issues email: [email protected]

Newsy Today
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World